H. Emama M.D.. (Radiation Therapy) By: H. Emami Assistant professor of Radiation Oncology, Isfahan University of Medical Sciences, Isfahan, IRAN.

Slides:



Advertisements
Similar presentations
بسم الله الرحمن الرحيم ﴿و قل رب زدنى علماً﴾ صدق الله العظيم.
Advertisements

Diagnosis.
Pulmonary Stereotactic Ablative Radiotherapy:
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
AJCC Staging Moments AJCC TNM Staging 7th Edition Rectal Case #3 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
Urostomy Why? Patricia Anderson BSN RN CWOCN. The American Cancer Society’s estimates for bladder cancer in the United States for 2013 are: About 72,570.
Rectal Cancer: A Complete Clinical Response…Now what?
Bladder tumors 3 times more common in men
Multidisciplinary approaches on chest tumors Radiation Oncology Case Reports.
Advanced squamous cell carcinoma of the bladder, What is next? Saleh A. Binsaleh.
High-Grade T1 Bladder Cancer: A Clinical Quandary Daniel Canter, M.D. Assistant Professor of Urology Emory University presentation created for:
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Impact of imaging on newer radiation techniques in Gynaecological cancer.
Bladder Cancer R. Zenhäusern. Bladder cancer: Epidemiology Incidence:20/100000/year (Europe) Mortality:8-9/100000/year Fourth most common cancer in men.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.
Esophageal Cancer, New updates in Chemoradiation Dr Hamid Reza Dehghan Manshadi Radiation Oncologist Iran University of Medical sciences.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Prof Ramesh S Bilimagga President AROI Group Medical Director - HCG.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.
Electronic Image Safe (Remove for final output). BCG Plus IFN-  Combination Therapy Rationale Evidence of synergistic activity Evidence of synergistic.
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
Prospective Phase II Study of Preoperative Radiotherapy and Oral Capecitabine followed by Total Mesorectal Exicision (TME) in Locally Advanced Rectal Cancer.
GIC Protocol Meeting Ca Stomach Presentor-Dr Richa Madhawi Moderator- Dr S. Pathy.
Management of muscle-invasive bladder cancer Todd M. Morgan Vanderbilt University.
Surgical Management of Urothelial Carcinoma A 21 st Century Approach Douglas S. Scherr, M.D. Clinical Director, Urologic Oncology Weill Medical College.
Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.
In the name of God Isfahan medical school Shahnaz Aram MD.
Preoperative CCRT in Colorectal Cancer 嘉義長庚醫院 大腸直腸外科 葉重宏.
Are there benefits from chemotherapy to early endometrial cancer
Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,
Current Role of Partial Cystectomy: Are we scarifying patient ’ s survival Dr Eric Li Department of Surgery Pamela Youde Nethersole hospital.
10/16/20151 UROTHELIAL CANCER E. Elamin, MD. 10/16/20152 Bladder : Ureters: Renal Pelvis Bladder : Ureters: Renal Pelvis 50 : 3 : 1 50 : 3 : 1.
1 CANCER OF THE BLADDER. 2  Cancer of the bladder is the second most common urologic malignancy.  90% of all bladder cancers are transitional cell carcinomas,
Dr. Abdellatif Zayed Bladder Cancer.
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
Urinary Bladder Anatomical sites of the urinary bladder. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer,
TNM BLADDER CANCER STAGING Dr. Mahnaz Roayaei Radiation Oncologist Assistant Professor Isfahan University of Medical Sciences.
Neoplasms of the bladder
Contemporary Treatment Guidelines on Bladder Cancer
In the name of God Cervical Cancer Dr.T allameh MD.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
LCC REC-1 Φ π π π Φ Φ See Primary and Adjuvant Treatment (LCC REC-3) Observe or See Primary Treatment (LCC REC-3) Rectal Cancer.
Background Carcinoma of the anal canal accounts for 1.5% of all digestive system malignancies in the United States. 1 The annual incidence continues to.
Bladder tumor dr,mohamed fawzi alshahwani 1. facts Bladder cancer is the second most common cancer of the genitourinary tract.Bladder cancer is the second.
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Role of Radiation Therapy in Brain metastasis Bongkot Supawongwattana, M.D. Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang.
Head & Neck Ca. (Epithelial tumors) Mohamad KADRI. MD. Clinical oncology. Medical director of AlBerouni University Hospital President of Syrian Association.
أورام المثانة Bladder cancer Dr.Alseoudi Alhadi د.الهادي السعودي Albairouni C.H.U.
Bladder Cancer Mark Browning, M.D. ‘ IUSME.
Taipei Veterans General Hospital Practices Guidelines Oncology Rectal Cancer Version
Management of Ca Urinary Bladder
Bladder Cancer R. Zenhäusern.
SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance
Radiation therapy for Early Stage Prostate Cancer
Nasopharyngeal carcinoma
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Bladder Cancer and Prostatic Cancer
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
Management of Invasive Bladder Cancer
Institute of Oncology “Ion Chiricuță”, Cluj, Romania
盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全, 吳昆霖
What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases?
Systemic chemotherapy->chemoradiation->surgery.
Volume 61, Issue 5, Pages (May 2012)
Adjuvant Radiation is Required for Gastric Cancer
Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program
Presentation transcript:

H. Emama M.D.

(Radiation Therapy) By: H. Emami Assistant professor of Radiation Oncology, Isfahan University of Medical Sciences, Isfahan, IRAN.

Superficial tumors TUR (standard) Interavesical therapy Or Radical Cystectomy Or Bladder preserving Low grade, Low stage Observation High grade, High stage, Multifocal CIS Multifocal Tumors Tumor associated with CIS If rapidly recur

Muscle invasion (T2) Radical Cystectomy (standard) + CT CT + Radical Cystectomy if nodes are Negative (NCCN) category 1 Chemoradiation + CT CT + Chemoradiation Partial Cystectomy + CT CT + Partial Cystectomy (NCCN) Bladder Preservation

Muscle invasion (T2) TURBT Chemo-radiation ( Gy) Cystoscopic Evaluation Consolidation Chemo-radiation (64 – 66 Gy) Radical Cystectomy CRIn-CR Recurrence

Perivesical fat invasion (T3) CT + Chemoradiation CT + Radical Cystectomy (NCCN) category 1 Pre-op. Chemoradiation + Cystectomy + Post op. Chemotherapy

Adjacent organ (s) involvement(T4a) CT + Chemoradiation CT + Radical Cystectomy in selected patient Involvement of pelvic or Abdominal wall (T4b) Chemoradiation Palliative therapy Radiation therapy Chemotherapy

T2 T3 Selected T4a Pre-op. Chemoradiation or Chemotherapy (for down staging) Post op. Chemoradiation (In high risk patients) Residue Positive LN(s) (Chemoradiation Therapy) Node negative No New Bladder

1)-5000 cGy to the whole pelvis. 2)-Lateral boost to the bladder (1000 cGy). 3)-Cystectomy (4 to 6 week later). 1) cGy to the whole pelvis + bladder boost Total dose cGy + Cisplatin, Carboplatin, Paclitaxel, 5FU, Gemcitabine (low dose )(33mg/m 2 twice weekly) Mytomycin-C + 5FU (NCCN) 2)- Two course MCV, then Chemoradiation Pre-op. Radiation therapy Or Chemoradiation (for down staging) Chemoradiation therapy (for bladder preservation) (Radiation Therapy)

Bone metastasis Hematuria Lung and Liver Met. Chemotherapy 3000 CGY in 10 fractions CGY in 20 fractions cGy in one fraction cGy every 3-4 week for 3 times 600 cGy every week for 5 weeks (Palliative Therapy)

1)-Convential ( cGy/day) (Total 6400 cGy) 2)-Hyper fractionation (100 cGy X 3 times/day) (total 8400 cGy) 1000 cGy in one fraction 2100 cGy in 3 fractions 3)-Hypo fractionation 3500 cGy in 10 fractions 600 cGy weekly (total 3000 cGy 600 cGy weekly (total 3600 cGy) (Radiation Therapy Schedule)

(Radiation Therapy Techniques) Anterior-posterior portal Right lateral portal

Box Tech. (whole pelvis) Box Tech. (Bladder) (Radiation Therapy Techniques)

Two Lateral Arc Technique Three Field Arrangement (Radiation Therapy Techniques)

-External beam radiation is rarely appropriate for patients with recurrent Ta and T1 tumor or diffuse Tis. -simulate and treat patients with bladder empty. -use multiple fields from high-energy linear accelerator beams. -Treat the whole bladder with or without pelvic lymph nodes with Gy and then boost the bladder tumor to total dose of Gy. -Consider low-dose pre-operative radiation prior to segmental resection for invasive tumors. (Radiation Therapy)